Evaluation of Safety of Levocetirizine in Routine Clinical Practice-non- Interventional Study

UCB

Status: Completed

Conditions: Rhinitis Allergic, Persistent

Study type: Observational

Funder types: Industry

Identifiers

NCT00598780

A00421

Details and patient eligibility

About

To evaluate over a period of 6 months the safety and the treatment satisfaction of newly prescribed levocetirizine in patients of age ≥ 2 years with persistent allergic rhinitis.

Full description

This is a non-interventional, prospective, post-authorization, multi-centre cohort study in patients treated with levocetirizine.

The baseline data will be collected at the visit to the physician when levocetirizine is prescribed for the first time for the patient for Persistent Allergic Rhinitis. The data will then be collected during 2 visits occurring within the first 6 months of treatment, as usually scheduled in normal clinical practice in the Czech and Slovak Republics. This is after approximately 4 weeks and 6 months of treatment or earlier, if the treatment is stopped

Enrollment: 7,870 patients

Sex: All

Ages: 2+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• diagnosis of persistent allergic rhinitis
• first prescription of levocetirizine for this diagnosis for this patient
• age ≥ 2 years

Exclusion criteria

• indications other than those defined in inclusion criteria
• history of allergic or anaphylactic reactions to levocetirizine or other derivatives and excipients included

Trial design

7,870 participants in 1 patient group

1

Description:

Patients with newly diagnosed persistent allergic rhinitis, within the approved age limits.